AzTrials
AzTrials

Postoperative PainCGFNCT03913884

Effect of CGF on Short Term Clinical Outcomes After Partially Impacted Mandibular Third Molar Surgery

A study testing Concentrated growth factor and Non-Concentrated growth factor Group in people with Postoperative Pain and Trismus, run by Ege University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study was to evaluate the effectiveness of concentrated growth factor (CGF) on soft tissue healing and postoperative side effects following third molar surgery. This study was designed on 60 patients as a randomized single-blind clinical trial. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Postoperative Pain, Trismus, Edema
What is being tested?
Concentrated growth factor and Non-Concentrated growth factor Group
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteTurkey (Türkiye)
Study dates
4 Apr 2018to 26 Aug 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • 1- Bilateral, vertically, partially-impacted Class I, Level B third molars

Who cannot join

  • Infection of the surgical region
  • Smoking habit
  • Alcohol usage
  • Physical or mental disability
  • Thrombocytopenia
  • Chemotherapy in head and neck region
  • Pregnant woman or woman in menstrual cycle

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Ege University, Faculty of Dentistry

    Izmir, Bornova, 35040

Other trials in Turkey (Türkiye)

About this study

Official title: Effect of Concentrated Growth Factor (CGF) on Short Term Clinical Outcomes After Partially Impacted Mandibular Third Molar Surgery: A Split-Mouth Randomized Clinical Study

The aim of this study was to evaluate the effectiveness of concentrated growth factor (CGF) on soft tissue healing and postoperative side effects following third molar surgery. This study was designed on 60 patients as a randomized single-blind clinical trial. The predictor variable was the implementation of CGF fibrin matrix, which was categorized as CGF and non-CGF. The primary outcome variable of the study was the healing of soft tissue around the extraction socket. The secondary outcome variables were pain, swelling and trismus. Data were analyzed using the non-parametric Brunner and Langer model. Statistical significance was set at P < .001.

Read the detailed description

The study population was composed of subjects presenting to the Department of Oral Surgery for evaluation and management of bilateral, partially-impacted mandibular third molars. The protocol for this study was approved by the local ethics committee and all participants signed an informed consent.

A patient who was referred for extraction of mandibular third molars was examined clinically and radiologically according to the inclusion criteria.

Before the partially-impacted mandibular third molar surgery, randomisation was achieved by use of sealed envelopes, selected by the patient. The envelopes contained cards labelled 'right' or 'left', which indicated the surgical side to receive CGF application.The envelopes were opened by the surgeon after the patients made their selection.

Both partially-impacted mandibular third molars were extracted by the same experienced surgeon. For each patient, the sites operated on were randomly divided into two study groups.

Group I (test); in which CGF fibrin matrix was applied to the extraction socket Group II (control); in which CGF was not applied to the extraction socket Each patient was listed for two surgical appointments. The second extraction was done on the control side, three weeks after the first extraction.

Patients were blind as to which side the CGF was placed, in order to avoid any influence on visual analog scale (VAS) scores. To obtain an objective assessment of pain, patients were informed that CGF application was used on all sites by the surgeon. The surgeon was not blind to the CGF application or the suturing. Therefore, clinical parameters were assessed based on the classifications by an independent observer specializing in oral surgery.

Study variables The primary variable of this clinical study was CGF application. CGF Preparation CGF was prepared according to Sacco protocol. The patients' blood was collected in 9 ml glass two tubes with vacutainer. The tubes were centrifuged immediately in a special centrifuge device (Medifuge, France). After the following settings were used: 2 min 2700 rpm, 4 min 2400 rpm, 4 min 2700 rpm and 3 min 3000 rpm, three layers were observed in the tubes. The upper layer, comprising platelet-poor plasma and the lower one, the red blood cells, were separated from the 'buffy coat', the CGF, by forceps and scissors.

The primary outcome variable was soft tissue healing around the extraction socket. The secondary outcome variables were pain, swelling and trismus.

Before surgery, patients rinsed their mouths with 0.12% clorhexidine gluconate as an antiseptic mouthwash for 60 seconds.

All surgeries were carried out using the same protocol by the same experienced surgeon. As local anesthetic, 2% lidocaine with 1:80.000 epinephrine (1/200.000 Jetokain®, Adeka, İstanbul, Turkey) was applied. A mucoperiosteal flap was elevated to expand initial access without releasing. The surgical approach for each tooth was as follows: bone removal, simple mobilization, extraction of tooth without sectioning and curettage of the socket. After extraction, the socket was irrigated using 60 mL of sterile saline.

CGF fibrin matrix was placed in one socket which was randomly selected (test side). After three weeks, extraction of the tooth on the opposite site was performed and the socket left to heal naturally (control side). The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.

Postoperatively, amoxicillin (500 mg/8 h, Largopen®, Bilim Pharmaceuticals, İstanbul, Turkey for five days), 0.2% chlorhexidine mouthwash (twice per day for seven days; Kloroben®, Drogsan Pharmaceuticals, Ankara, Turkey) and paracetamol (500 mg, every 4-6 h, Parol®, Atabay Pharmaceuticals, İstanbul, Turkey) were prescribed by the surgeon. After one week, sutures were removed.

All subjects were recalled postoperatively at the 3rd and 7th days by the blinded examiner. Soft tissue healing, pain, swelling and trismus were evaluated on the 3rd and 7th days and pain scores, noted from 1st to 7th days by the patient, were collected. Demographic values for patients' age and gender were also noted.

Being tested
Concentrated growth factor, Non-Concentrated growth factor Group
Keywords
Impacted third molar surgery, Clinical outcomes, Concentrated growth factor
Medical subject headings
Pain, Postoperative, Trismus, Edema

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Concentrated growth factorProcedure or surgery

    CGF fibrin matrix was placed in one socket which was randomly selected (test side). The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.

  • Non-Concentrated growth factor GroupOther

    To control group, extraction of the tooth on the opposite site was performed and the socket left to heal naturally. The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.

Study groups in NCT03913884
Study groupRoleWhat they receive
Concentrated growth factor GroupExperimentalGroup I (test); in which CGF fibrin matrix was applied to the extraction socket
Receives: Procedure: Concentrated growth factor
Non-Concentrated growth factor GroupExperimentalGroup II (control); in which CGF was not applied to the extraction socket
Receives: Other: Non-Concentrated growth factor Group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. soft tissue healing

    This was assessed on the third and seventh preoperative days using the healing index classified by Landry et al.12. It depends on tissue colour, presence of bleeding on palpation, epithelization of wound margins, granulation tissue and suppuration, and rates the degree of healing attained from 'very poor' to 'excellent'.

    Measured: Change of soft tissue healing at 7 days

Secondary outcomes (3)
  1. severity of postoperative pain

    The patients were instructed to note their level of postoperative discomfort and/or pain on the scale, which ranged from 0, indicating no pain, to 100 indicating the worst ever experienced. Paracetamol (500-mg tablets) was prescribed to be taken postoperatively as needed. The patients were asked to fill in the questionnaire as required on a daily basis for 7 days.

    Measured: Change of postoperative pain at 7 days

  2. presence of swelling

    three facial measurements were taken with milimetric elastic ruler, preoperatively, as described by Kumar et al., on the third and seventh days after extraction. These dimensions were as follows: the from the tragus to the pogonion (TP); from the tragus to the corner of the mouth (TC); and from the lateral corner of the eye to the angle of the mandible (EA).

    Measured: Change of swelling at 7 days

  3. presence of trismus

    Inter-incisal distance was measured, as a guide point, with a millimeter ruler.

    Measured: Change of trismus at 7 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Apr 2019
  2. Study start4 Apr 2018
  3. Primary completion19 Aug 2018
  4. Study completion26 Aug 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Sequential
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03913884
Sponsor's protocol ID
Faculty of Dentistry
Acronym
CGF
Status last verified
Apr 2019
First submitted
10 Apr 2019
Last updated
16 Apr 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Ozveri Koyuncu B, Isik G, Ozden Yuce M, Gunbay S, Gunbay T. Effect of concentrated growth factor (CGF) on short-term clinical outcomes after partially impacted mandibular third molar surgery: A split-mouth randomized clinical study. J Stomatol Oral Maxillofac Surg. 2020 Apr;121(2):118-123. doi: 10.1016/j.jormas.2019.07.002. Epub 2019 Jul 9.

    PubMed 31299343

Questions about this trial

What is this clinical trial studying?

A study testing Concentrated growth factor and Non-Concentrated growth factor Group in people with Postoperative Pain and Trismus, run by Ege University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

soft tissue healing (time frame: Change of soft tissue healing at 7 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03913884, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in